

FLUCONAZOLE (Commentary)

Prophylactic use in very preterm babies

Use of fluconazole: Systemic *Candida* infection is currently encountered in some 7% of all babies weighing less than 1 kg at birth in the America (Benjamin *et al.*, 2006), but in only about 2% of these babies in the UK (Clerihew *et al.*, 2006). Prevalence varies widely – the problem is commoner in some units than in others, and in some countries than in others. Almost a third of all the children of less than 1.5 kg at birth in the placebo arm of a recent Italian trial were colonized, and 13% developed invasive fungal infection (Manzoni *et al.*, 2007). The prognosis for the 7% of babies of less than 1 kg at birth who *did* develop systemic *Candida* infection while receiving care in a NICHD Research Network Hospital in America in 1998-2001 was very poor: a third died and half the survivors showed evidence of neurodevelopmental impairment at 18–22 months (Benjamin *et al.*, 2006). Systemic infection often persisted for many days, especially if the ‘long line’ was not removed or replaced within a day, and a single negative blood culture could not be relied upon to show that infection had been eradicated (as Chapman and Faix, and Karlowicz *et al.*, had found eight years earlier). Indeed half the babies with fungal CNS infection in the NICHD study had had at least one falsely reassuring negative blood culture. The use of a cephalosporin, and delayed enteral feeding, both made systemic infection more likely. In another recent study (Feja *et al.*, 2005) systemic fungal infection was also more common in babies who had previously had a documented episode of bacterial sepsis or evidence of necrotizing enterocolitis – a feature that strongly suggests that widespread broad-spectrum antibiotic use is a major contributory factor.

There has, as a result, been mounting interest in the **prophylactic** use of oral or IV fluconazole to keep colonisation in check, and so reduce the risk that this will then evolve into systemic fungal infection. Such an approach was described some years ago in the management of patients with AIDS and with leukaemia, and validated in at least two randomized controlled trials (Leen *et al.*, 1990; Winston *et al.*, 1993). However, in a more recently published trial, its more general empirical use was not found to improve outcome in seriously ill adults in intensive care with an unexplained fever despite antibiotic treatment (Schuster *et al.*, 2008). Similarly, while a meta-analysis of four trials of its routine use in adult patients required surgical intensive care (Shorr *et al.*, 2005) found that fluconazole halved the rate of documented fungal infection, it did little to improve survival rates.

A steady stream of observational studies have been published since 2001 suggesting that prophylaxis can also be useful the very low birth weight baby, and a meta-analysis of four randomised trials have now confirmed that such an approach does reduce the risk of invasive fungal infection (Clerihew *et al.*, 2008). There is also a suggestion from the largest of these four trials – an Italian study involving 322 babies of less than 1.5 kg – that *low* dose prophylaxis (3 mg/kg IV or by mouth once every three days for two weeks and then once every other day for another 2–4 weeks) started routinely three days after birth may be just as effective as a dose twice this big (Manzoni *et al.*, 2007).

Many are now recommending routine prophylaxis for all high risk babies “early enough to prevent colonization, ideally on the first postnatal day” and continuing this for 36 weeks (Healy and Baker, 2009). However, such views still leave many skeptical as to whether *routine* prophylaxis is really wise (Neely and Schreiber, 2001; Long and Stephenson, 2005; Benjamin, 2008) and there is, as yet, no evidence that the decrease in the incidence of overt fungal infection leads to any improvement in survival to discharge, or in the risk of disability in those who do survive. Similarly, while there is little evidence that the widespread use of fluconazole has yet started to cause drug resistant fungal strains to emerge (Roilides *et al.*, 2004; Healy *et al.*, 2008; Manzoni *et al.*, 2008), there are signs that this could happen (Sarvikivi *et al.*, 2005; Giusiano *et al.*, 2005; Khan *et al.*, 2007), and it could become a serious problem with widespread use. Several groups are certainly now suggesting that a more selective approach that targets just the most vulnerable babies for short-term treatment may be a wiser strategy (Uko *et al.*, 2006; McCrossan *et al.*, 2008).

Alternative strategies: Some would even suggest that the prophylactic use of a systemically absorbed drug to deal with a problem that is probably caused by excessive broad spectrum antibiotic use in the first place is the ‘lazy option’, and that more should be done to try and find out *why* systemic fungal infection is so much more common in some units than it is in others. If heavy colonization of the skin and intestinal tract with *Candida* was not so prevalent in the first place, near universal prophylaxis would not be necessary. One reason may be that some units use IV alimentation for much longer than others, and another that units also vary in the diligence with which these lines are inserted and cared for (O’Grady *et al.*, 2002; McGee and Gould, 2003)

There is also at least one simpler and cheaper approach that has, to date, gone largely ignored. A small single-centre trial involving 67 babies weighing less than 1.25 kg at birth (Sims *et al.*, 1988) showed, twenty years ago, that the prophylactic use of oral nystatin (which is not absorbed into the blood stream

when given by mouth) could also substantially reduce the risk of systemic fungal infection (32 v. 6%). Recent studies from France (Borderon *et al.*, 2003), from Turkey (Ozturk *et al.*, 2006), and from America (Srinivasan *et al.*, 2007), have confirmed that, if hand washing is done carefully enough to prevent *Candida* spreading from patient to patient, and if oral nystatin is started as soon as colonisation is suspected, systemic fungal infection becomes rare even in very low birth weight babies. An observational study in Liverpool between 1998 and 2003 also seemed to show that prophylaxis with nystatin is capable of reducing the incidence of invasive fungaemia (Ganesan *et al.*, 2009). Professor Manzoni and his colleagues wonder, however, whether the use of nystatin may be masking the true incidence of invasive *Candida* infection, and would argue that any definition of systemic infection must, at the very least, include all cases where *Candida* is cultured from urine, CSF or peritoneal fluid as well as from blood (Manzoni *et al.*, 2009). Most would however agree with the conclusion of this recent review that routine fluconazole prophylaxis is probably not indicated in any unit where, with other approaches to general care, fewer than 5% of the babies at greatest risk are currently developing systemic infection.

Click [here](#) for a copy of the full report issued by the Hospital Infection Control Practices Advisory Committee (HICPAC report) of the Centers for Disease Control and Prevention (CDC) in America also summarized in the paper by O'Grady *et al.* in 2002.

References

- Sims ME, Too Y, You H, *et al.* Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. *Am J Perinatol* 1988;**5**:33–6. [RCT]
- Leen CL, Dunbar EM, Ellis ME, *et al.* Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. *J Infect* 1990;**21**:55–60. [RCT]
- Winston DJ, Chandrasekar PH, Lazarus HM, *et al.* Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Results of a randomized placebo-controlled, double blind, multicentre trial. *Ann Intern Med* 1993;**118**:495–503. [RCT]
- Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. *Pediatr Infect Dis J* 2000;**19**:882–7.
- Karlowicz MG, Hashimoto LN, Kelly RE, *et al.* Should central venous catheters be removed as soon as Candidemia is detected in neonates? *Pediatrics* 2000;**106**:e63.
- Kaulfman D, Boyle R, Hazen KC, *et al.* Fluconazole prophylaxis against fungal colonization and infection in preterm infants. *N Engl J Med* 2001;**345**:1660–6. [RCT] (See also 2002;**346**:1913–4.)
- Kicklighter SD, Springer SC, Cox T, *et al.* Fluconazole for prophylaxis against candidal rectal colonisation in the very low birthweight infant. *Pediatrics* 2001;**107**:293–8. [RCT] (See also 404–6).
- Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. [Commentary] *Pediatrics* 2001;**107**:404–6.
- O'Grady NP, Alexander M, Dellinger RP, *et al.* Guidelines for the prevention of intravascular catheter-related infections *Pediatrics* 2002;**110**:e51.
- Cabrera C, Frank M, Carter D, *et al.* Fluconazole prophylaxis against systemic candidiasis after colonization: a randomized double-blinded study. [Abstract] *J Perinatol* 2002;**22**:604. [RCT]
- McGee DC, Gould MK. Preventing complications of central venous catheterization. [Review] *N Engl J Med* 2003;**348**:1123–33.
- Borderon JC, Therizol FM, Saliba E, *et al.* Prevention of *Candida* colonisation prevents infection in a neonatal unit. *Biol Neonate* 2003;**84**:37–40.
- Roilides E, Farmaki E, Evdoridou J, *et al.* Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. *Eur J Clin Microbiol Infect Dis* 2004;**23**:745–50.
- Shorr AF, Chung K, Jackson WL, *et al.* Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. *Crit Care Med* 2005;**33**:1928–35. [SR]
- Kaufmann DA, Gurka MJ, Hazen KC, *et al.* Patterns of fungal colonisation in preterm infants weighing less than 1000 grams at birth. *Pediatr Infect Dis J* 2005;**25**:733–7.
- Dutta S, Murki S, Varma S, *et al.* Effects of cessation of a policy of neonatal fluconazole prophylaxis on fungal resurgence. *Indian Pediatr* 2005;**42**:1226–30.
- Long SS, Stephenson DK. Reducing *Candida* infections during neonatal intensive care: management choices, infection control and fluconazole prophylaxis. [Editorial] *J Pediatr* 2005;**147**:135–41.
- Feja KN, Wu F, Roberts K, *et al.* Risk factors for candidemia in critically ill infants: a matched case-control study. *J Pediatr* 2005;**147**:156–61.
- Bertini G, Dani S, Filippi L, *et al.* Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. *J Pediatr* 2005;**147**:162–5.
- Healy CM, Baker CJU, Zaccaria E, *et al.* Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. *J Pediatr* 2005;**147**:166–71.
- Kaufman D, Boyle R, Hazen KC, *et al.* Twice weekly fluconazole for prevention of invasive *Candida* infection in high-risk infants of <1000 grams birth weight. *J Pediatr* 2005;**147**:172–9.
- Sarvikivi E, Lyytikäinen O, Soli DR, *et al.* Emergence of fluconazole resistance in a *Candida parapsilosis* strain that caused infections in a neonatal intensive care unit. *J Clin Microbiol* 2005;**43**:2729–35.
- Giusiano G, Mangiaterra M, Rojas F, *et al.* Azole resistance in neonatal intensive care units in Argentina. *J Chemother* 2005;**17**:347–50.
- Ozturk MA, Gunes T, Kolku E, *et al.* Oral nystatin to prevent invasive candidiasis in neonatal intensive care unit. *Mycoses* 2006;**49**:484–92. [RCT]
- Manzoni P, Arisio R, Mostert M, *et al.* Prophylactic fluconazole is effective in preventing fungal colonisation and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. *Pediatrics* 2006;**117**:e22–32. (See also 214–5.)
- Manzoni P, Fasrina D, Leonessa M, *et al.* Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. *Pediatrics* 2006;**118**:2359–64.
- Burwell LA, Kaufman D, Blakely J, *et al.* Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. *Pediatrics* 2006;**118**:e1019–26.

- Benjamin DK, Stoll BJ, Fanaroff AA, *et al.* Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 11 to 22 months. *Pediatrics* 2006;**117**:84–92.
- Mendiratta DK, Rawat V, Thamke D, *et al.* Candida colonization in preterm babies admitted to neonatal intensive care unit in a rural setting. *Indian J Med Microbiol* 2006;**24**:263–7.
- Uko S, Soghier LM, Vego M, *et al.* Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. *Pediatrics* 2006;**117**:1243–52.
- Clerihew L, Lamagni TL, Brocklehurst P, *et al.* Invasive fungal infection in very low birthweight infants: national prospective surveillance study. *Arch Dis Child* 2006;**91**:F188–92.
- Srinivasan HB, Srinivasan G. Topical/oral nystatin prophylaxis for prevention of fungal sepsis in VLBW infants. [Abstract 435] *Pediatric Academic Societies' Annual Meeting Toronto*, 2007.
- Clerihew L, Lamagni TL, Brocklehurst P, *et al.* Candida parapsilosis infection in very low birthweight infants. *Arch Dis Child* 2007;**92**:F127–9.
- Khan ZU, Al Sweih NA, Ahmad S, *et al.* Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole and fluconazole. *J Clin Microbiol* 2007;**45**:2025–7.
- Parikh TB, Nanavati RN, Patankar CV, *et al.* Fluconazole prophylaxis against fungal colonisation and invasive fungal infection in very low birth weight infants. *Indian Pediatr* 2007;**44**:830–7. [RCT]
- McCrossan BA, McHenry E, O'Neil F, *et al.* Selective fluconazole prophylaxis in high risk babies to reduce invasive fungal infection. *Arch Dis Child* 2008;**92**:F454–8.
- Manzoni P, Stolfi I, Pugni L, *et al.* A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. *N Engl J Med* 2007;**356**:2483–95. [RCT] (See also 2007;**357**:1348–9.)
- Manzoni P, Leonessa M, Galletto P, *et al.* Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant candida subspecies. *Pediatr Infect Dis J* 2008;**27**:731–7.
- Clerihew L, McGuire W. Antifungal prophylaxis for very-low-birth-weight infants: UK National study. *Arch Dis Child* 2008;**93**:F198–9.
- Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. *Arch Dis Child* 2008;**93**:F198–200. [SR]
- O'Grady MJ, Dempsey EM. Antifungal prophylaxis for the prevention of neonatal candidiasis? *Acta Paediatr* 2008;**97**:430–3.
- Healy CM, Campbell JR, Zaccaria E, *et al.* Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive Candidiasis mortality rates without emergence of fluconazole-resistant Candida species. *Pediatrics* 2008;**121**:703–10. (See also 831–2.)
- Benjamin DK. First, do no harm. [Commentary] *Pediatrics* 2008;**121**:831–2. (See also 1158–9.)
- Carey AJ, Saiman L, Polin RA. Hospital-acquired infections in the NICU: epidemiology for the new millennium. [Review] *Clin Perinatol* 2008;**35**:223–49.
- WeitcampJ-H, Ozdas A, LaFleur B, *et al.* Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. *J Perinatol* 2008;**28**:405–11.
- Schurster MG, Edwards JE, Sobel JD, *et al.* Empirical fluconazole versus placebo for intensive care unit patients. *Ann Intern med* 2008;**149**:83–90. [RCT] (See also 1401.)
- Healy CM, Baker CJ. Fluconazole prophylaxis in the neonatal intensive care unit. *Pediatr Infect Dis J* 2009;**28**:49–51.
- Ganesan K, Hanigopal S, Neal T, *et al.* Prophylactic oral nystatin for preterm babies under 33 weeks gestation decreases fungal colonisation and invasive fungaemia. *Arch Dis Child* 2009;**94**:F275–8.
- Blyth CC, Chen SCA, Slavin MA, *et al.* Not just little adults: Candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. *Pediatrics* 2009;**123**:1360–8.
- Manzoni P, Mostert M, Jacqz-Algrain E, *et al.* The use of fluconazole in neonatal intensive care units. [Review] *Arch Dis Child* 2009. Published first on line 21.8.09. doi:10.1136/adc.154385.

Efficacy and pharmacokinetics

Postnatal age has a significant impact on the pharmacokinetics of fluconazole, but this is a subject that has been reasonably well studied. While oral treatment delivers blood levels that are almost as high as IV treatment, there is increasing evidence that most reference texts currently recommend a dosage regime for the neonate that may well not be therapeutic if the *Candida* organism involved has a moderately high minimum inhibitory concentration (MIC), and Wade *et al.* 2009 have recommended a dose of 12 mg/kg once a day in order to be sure of giving enough to eliminate systematic infection where the organism has a MIC of $\leq 8 \mu\text{g/ml}$. They also point that, given the long half life, such a level will not be achieved for 2–3 days if no initial loading dose is given. Although this is the dose now recommended by this *Formulary*, its safety requires further study.

There is one report suggesting that neonatal use may be associated with a higher incidence of cholestasis (Aghai *et al.*, 2006), but no such association could be found after allowing for the confounding effect of the common use of parenteral nutrition in a later larger study (Healy *et al.*, 2008). Widespread neonatal use both to prevent and to treat *Candida* infection does not seem to have resulted, as yet, in the emergence of many organisms that are resistant to this useful antifungal drug, but it is a problem that could arise at any time (see above). Maternal treatment during lactation only exposes the baby to ~10% of the weight-adjusted maternal dose, and no authority has ever suggested that such exposure could be harmful.

Saxén H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. *Clin Pharmacol Ther* 1993;**54**:269–77.

Fasano D, O'Keefe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. *Eur J Clin Microbiol Infect Dis* 1994;**13**:351–4.

Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. *Eur J Clin Microbiol Infect Dis* 1994;**13**:325–9.

Ng PC. Systemic fungal infections in neonates. *Arch Dis Child* 1994;**71**:F130–5.

Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. *Eur J Clin Microbiol Infect Dis* 1994;**13**:325–9.

- Gurses N, Kalayci AG. Fluconazole monotherapy for candidal meningitis in a premature infant. *Clin Infect Dis* 1996;**23**:645–6.
- Driessen M, Ellis JF, Copoper PA, *et al.* Fluconazole vs amphotericin B for the treatment of neonatal fungal septicaemia: a prospective randomized trial. *Pediatr Infect Dis J* 1996;**15**:1107–12. [RCT]
- Wainer S, Cooper P, Gouws H, *et al.* Prospective study of fluconazole therapy in systemic neonatal fungal infection. *Pediatr Infect Dis J* 1997;**16**:763–9.
- Wong S-F, Leung MP, Chan M-Y. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. *Clin Ther* 1997;**19**:1039–47.
- Wenzl TG, Schefels J, Hörnchen H, *et al.* Pharmacokinetics of oral fluconazole in premature infants. *Eur J Pediatr* 1998;**157**:661–2.
- Huttova M, Hartmanova I, Kralinsky K, *et al.* Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. *Pediatr Infect Dis J* 1998;**17**:1012–5.
- Novelli V, Holzel H. Safety and tolerability of fluconazole in children. *Antimicrob Agents Chemother* 1999;**43**:1955–60.
- Schwarze R, Penk A, Pittrow L. Administration of fluconazole in children below 1 year of age. *Mycoses* 1999;**42**:3–16.
- Robinson L-G, Jain L, Kourtis AP. Persistent candidemia in a premature infant treated with fluconazole. *Pediatr Infect Dis J*. 1999;**18**:735–9.
- Nahata MC, Tallian KB, Force RW. Pharmacokinetics of fluconazole in young infants. *Eur J Drug Metab Pharmacokinet* 1999;**24**:155–7.
- Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. *Pediatr Infect Dis J* 2000;**19**:822–7.
- Goins RA, Ascher D, Waecker N, *et al.* Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. *Pediatr Infect Dis J* 2002;**21**:1165–7. [RCT]
- Rollides E, Farmaki E, Evdoridou L, *et al.* Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. *Eur J Clin Microbiol Infect Dis* 2004;**23**:745–50.
- Lopez RE, van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. [Abstract] *Birth Def Res A* 2004;**70**:261.
- Befeltowshka JJ, Buszman E. Pharmacokinetics of fluconazole in the cerebral spinal fluid of children with hydrocephalus. *Chemotherapy* 2005;**51**:370–6.
- Giusiano G, Mangiaterra M, Rojas F, *et al.* Azole resistance in neonatal intensive care units in Argentina. *J Chemother* 2005;**17**:347–50.
- Aghai ZH, Mudduluru M, Nakhla TA, *et al.* Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. *J Perinatol* 2006;**26**:550–5.
- Healy CM, Campbell JR, Zaccaria E, *et al.* Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive Candidiasis mortality rates without emergence of fluconazole-resistant *Candida* species. *Pediatrics* 2008;**121**:703–10. (See also 831–2.)
- Gghai ZH, Mudduluru M, Nakhla TA, *et al.* Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. *J Perinatol* 2008;**36**:550–5.
- Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. *Paediatr Drugs* 2007;**9**:311–21. [SR]
- Wade KC, Wu D, Kaufman DA, *et al.* Population pharmacokinetics of fluconazole in young infants. *Antimicrob Agents Chemother* 2008;**52**:4043–9.
- Wade KC, Benjamin DK, Kaufman DA, *et al.* Fluconazole dosing for the prevention or treatment of invasive Candidiasis in young infants. *Pediatr Infect Dis J* 2009;**28**:717–23.

Slow IV administration

Many texts offer very firm advice as to how quickly it is safe to give this drug IV, but few state the reasoning behind the advice on offer, and the advice varies to widely that much of it must be wrong. Most paediatric texts in the UK including the *BNF* and *BNF-C* suggest that fluconazole can be given over 10–30 minutes, but one major American reference text (Taketomo's *Pediatric Dosage Handbook*) says it should be given "over 1–2 hours". The manufacturer's advice in the UK is that adults can normally be given their standard 200 mg IV dose over about 10 minutes, but the advice offered in America is that this dose should be given over an hour. Australian texts offer similar advice. There are no reports to suggest that rapid bolus administration is toxic, and no adverse reports associated with slow (but untimed) IV administration given over about 10 minutes in the manner advocated on page 6 of this *Formulary*.

Taketomo CK, Hodding JH, Kraus DM, eds. *Pediatric dosage handbook. Including neonatal dosing, drug administration & extemporaneous preparations*. 16th ed. Hudson, Ohio: Lexi-comp; 2009.

British National Formulary. *BNF for children*. London: Royal Pharmaceutical Society, 2009.

Use during pregnancy and lactation

High dose systemic exposure (400 mg/day) in the first trimester of pregnancy can produce a constellation of serious fetal abnormalities, but there are, as yet, no reports of teratogenicity with a single 150 mg dose in the first trimester, or with topical or oral use later in pregnancy. Systemic use by the mother during lactation will result in the baby receiving a substantial amount of the drug (~10% of the maternal dose on a weight-for-weight basis), but there is, as earlier sections of this review have shown that, no evidence that exposure to the much higher doses used during routine prophylaxis ever does any harm, so mothers should not be allowed to worry about the fact that a small amount of any fluconazole that they take systemically will ever harm the baby.

Rubin PC, Wilton LV, Inman WHW. Fluconazole and pregnancy: results of a prescription event-monitoring study. *Int J Gynecol Obstet* 1992;**37**:(Suppl)25–7.

Lee BE, Feinberg M, Abraham JJ, *et al.* Congenital malformations in an infant born to a woman treated with fluconazole. *Pediatr Infect Dis J* 1992;**11**:1062–4.

Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis: a prescription-event monitoring study, with special reference to the outcome of pregnancy. *Eur J Clin Pharmacol* 1994;**46**:115–8.

- Force RW. Fluconazole concentrations in breast milk. *Pediatr Infect Dis J* 1995;**14**:235–6.
- Mastroiacovo P, Mazzone T, Botto LD, *et al.* Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. *Am J Obstet Gynecol* 1996;**175**:1645–50.
- Wiesinger EC, Mayerhofer S, Wenish C, *et al.* Fluconazole for *Candida albicans* sepsis induring pregnancy: case report and review of the literature. *Infection* 1996;**24**:263–6.
- Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy. *Am J Med Genet* 1997;**72**:253–6.
- King CT, Rogers PD, Cleary JD, *et al.* Antifungal therapy during pregnancy. [Review] *Clin Infect Dis* 1998;**27**:1152–60.
- Sørensen HT, Nielson LG, Olesen C, *et al.* Risk of malformations and other outcomes in children exposed to fluconazole in utero. *Br J Clin Pharmacol.* 1999;**48**:234–8.
- Lopez RE, van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. *Birth Defects Res Pt A* 2005;**73**:919–23.

Candida as a cause of maternal nipple pain

Superficial, and more particularly deeper, ductal, *Candida* infection is now widely thought to be responsible for the severe radiating nipple pain that some women experience during breast feeding. It is, however, a very poorly studied subject. Health professionals have subjected the issue to very little study while lay groups, who have very extensive experience of this issue, have found it almost impossible to get the funding needed to study the subject rigorously. Similarly, the drug company that initially had the patent for this product can see no point in funding the study of this problem (or making a move to get the product licensed for such use) because that patent has now expired..

Most pain, especially pain experienced when feeding is first becoming established, is due to poor positioning – an easily solved problem as long as the mother can get access to experienced support and advice from a group such as the UK Breastfeeding Network (whose help line is 0844 412 4664), the Australian Breastfeeding Association, or the La Leche League International in America. [See: www.breastfeedingnetwork.org.uk; www.breastfeeding.asn.au; and www.lalecheleague.org.] Unresolved engorgement, eczema, tongue-tie, are other occasional causes of pain. A suddenly tender, lumpy and inflamed breast is evidence that mastitis is developing, a problem reported at least once during a tenth of all lactations (Foxman *et al.*, 2002). Frequently, however, this is simply due to a breast duct becoming blocked, although secondary staphylococcal infection can occasionally develop as a result of this (Inch and Fisher, 1996), meriting antibiotic treatment (as outlined in the *Formulary* monograph on flucloxacillin).

Features that are held to suggest that the pain could be due to *Candida* infection include bilateral burning or stabbing pain, and pain that increases in intensity after a breastfeed has finished, and continues for up to an hour afterwards (Francis-Morrill *et al.*, 2004). A few cases seem to be a form of Raynaud's phenomenon (Anderson *et al.*, 2004), and this occasionally merits pharmacological intervention – giving these mothers a 30 mg slow release tablet of nifedipine (Adalat® Retard) once a day often brings rapid relief.

The absence of pyrexia, or of a localized red area on the breast, are suggestive, and many would hold the diagnosis to be much more plausible if the mother has recently had antibiotic treatment, and there are signs to suggest that the baby has oral thrush. Many feel that the appearance of the breast is of little help, although it is sometimes said that the nipple may become unusually pale, or tender and fiery red. It has only proved possible to culture *Candida* from a proportion of surface swabs and milk samples, and the results do not seem not to be reliable or informative enough to make this worth doing.

That very shrewd and experienced clinician Mavis Gunther noted that painful fissured nipples could often be colonized by *Candida* more than sixty years ago, but the entity only seems to have been widely written about for the first time by the Australian family planning doctor Lisa Amir in 1991, and the only two formal studies of the condition still remain the study that she summarized in 1996, and the study reported by the medical student Karen Tanguay from a breast feeding clinic in Calgary, Canada in 1994. Nevertheless, by the end of the decade the condition was accepted as a proven entity by almost every Board Certified Lactation Consultant and every member of the Academy of Breastfeeding Medicine in America (Brent, 2001). Others have remained more skeptical (Carmichael and Dixon, 2002) and Thomas Hale, the Pharmacist who has written the world's most widely read book on "Medications and Mothers' Milk", (www.ibreastfeeding.com) has recently begun to express doubt as to whether the condition really exists.

Such skepticism baffles those who have experienced rapid symptomatic relief within 3–4 days once finally started on antifungal treatment, but there is little doubt that the condition is currently over-diagnosed. It can not be stressed too strongly that poor positioning is by far the commonest cause of nipple pain and nipple trauma and not drug treatment is going to compensate for that. Nevertheless, once an experienced breastfeeding advisor has ruled out most other possibilities, a trial of treatment is the only effective way to make a positive diagnosis (and important to remember that poor positioning, nipple trauma, and active *Candida* infection can probably all co-exist).

Management: Treatment is only going to be effective if the mother and baby are both treated, and re-infection may well occur unless all dummies, nipple shields, bottle teats and plastic toys are washed and sterilised (and this may involve boiling everything for twenty minutes). Take great care with the disposal of nappies, and wash your hands meticulously afterwards. Try and ensure that each member of the

family has a separate towel. Treat possible oral thrush with miconazole oral gel (q.v.), smearing 1 ml of the gel carefully round the child's mouth and gums after a feed four times a day (Hoppe, 1997) and, simultaneously, smear a *small* amount of 2% miconazole cream on the nipples after every feed (while remembering to wipe anything that is still visible away again before starting the next feed). Do not be put off by the fact that the manufacturer has recently said they do not think the oral gel is safe to use in children less than 4 months old – this change of advice seems to have been triggered by a single report of a Dutch baby who choked badly after the mother smeared large amounts of the gel on her nipples immediately before putting her baby to the breast (De Vries, *et al.*, 2006). The change of advice was widely criticized as a quite unjustified defensive over-reaction to an event that caused no lasting harm and was simply due to the inappropriate use of the appropriate drug.

If the baby has more extensive *Candida* infection, there may be a case for giving nystatin as oral drops and/or ointment (q.v.). And do not be reluctant to offer the mother pain relief merely because she is breast feeding. Most mothers can be offered two 400 mg tablets of ibuprofen three times a day after food, while those who are asthmatic, have a stomach ulcer or are allergic to aspirin can, as an alternative, be advised to take two 500 mg tablets of paracetamol three or even four times a day.

Those with extensive experience of this condition believe that, if infection of the breast has become deep seated, it will only be eradicated if the mother is also given a course of oral fluconazole (even though the manufacturers do not have a license to recommend such treatment). Give an initial 150–300 mg loading dose, and then 50–100 mg twice a day by mouth for at least ten days. The symptoms should start to improve within three days and the diagnosis needs to be reconsidered if there is no improvement after a week, but treatment sometimes needs to be sustained for more than ten days if symptoms have been present for a long time.

Many have expressed concern at the thought of prescribing a systemic antifungal drug that is known to appear in human milk and be absorbed by the baby for some supposed infection for which there is no objective evidence. There are, however, many other conditions where we accept that a diagnosis has in fact been made if some quite specific treatment causes rapid symptomatic relief, and those who criticise the use of fluconazole, except in the context of a formal research trial, for a problem that shows every chance of bringing breast feeding to an end if no solution is quickly found, ought to be even more critical of the widespread prophylactic use to which the drug is now being put (see above) simply to reduce the *risk* of infection !

Gunther M. *Infant Feeding*. London: Methuen & Co Ltd, 1970:83.

Amir LH, Pakula S. Nipple pain, mastalgia and candidiasis in the lactating breast. *Austr NZ J Obstet Gynaecol* 1991;**31**:378–80.

Amir L. Thrush in the ducts ? *Med J Austr* 1991;**155**:853.

Amir, LH. *Candida* and the lactating breast: predisposing factors. *J Hum Lact* 1991;**7**:177–81.

Amir FH, Pakula S. Nipple pain, mastalgia and candidiasis in the lactating breast. *Obstet Gynecol Survey* 1992;**47**:623–4.

Tanguay KE, McBean MR, Jain E. Nipple candidosis among breastfeeding women. Case-control study of predisposing factors. *Can Fam Physician* 1994;**40**:1407–13.

Inch S, Fisher C. Mastitis: infection or inflammation ? *Practitioner*. 1995;**239**:472–6.

Amir LH, Garland SM, Dennerstein , *et al.* *Candida albicans*: is it associated with nipple pain in lactating women? *Gynecol Obstet Invest* 1996;**41**:30–4.

Bodley V, Powers D. Long term treatment of a breast feeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. *J Hum Lact* 1997;**13**:307–11.

Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. *Pediatr Infect Dis J* 1997;**16**:885–94.

Ward KA, Burton JL. Dermatologic diseases of the breast in young women. [General overview.] *Clin Dermatol* 1997;**15**:45–52.

Sachs M, Jones W. Breastfeeding and thrush. *MIDIRS Midwifery Digest* 1998;**8**:486–9.

Hoover K. Breast pain during lactation that resolved with fluconazole: two case studies. *J Hum Lact* 1999;**15**:98–9.

Brent NB. Thrush in the breastfeeding dyad: results of a survey of diagnosis and treatment. *Clin Pediatr* 2001;**40**:503–6.

Foxman B, D'Arcy H, Gillespie B, *et al.* Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. *Am J Epidemiol* 2002;**155**:103–14. (See also the Commentary by Ruth Lawrence, 155–6.)

Carmichael AR, Dixon JM. Is lactation mastitis and shooting breast pain experienced by women during lactation caused by *Candida albicans*? *Breast* 2002;**11**:88–90.

Francis-Morrill J, Heihig MJ, Pappagianis D, *et al.* Diagnostic value of signs and symptoms of mammary candidosis among lactating women. *J Hum Lact* 2004;**20**:288–95.

Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. *Pediatrics* 2004;**113**:e360–4.

De Vries TW, Wewerinke ME, de Langen JJ. [Near asphyxiation of a neonate due to miconazole oral gel.] *Ned Tijdschr Geneesk* 2004;**148**:1598–600.

Weiner S. Diagnosis and management of candida of the nipple and breast. *J Midwifery Women's Health* 2006;**51**:125–8.

Hale TW. *Medications and mothers' milk*. 2008. 13th edition. Amarillo, Texas: Pharmasoft Publishing, 2008.

Ainsworth S, Jones W. It sticks in our throats too. [Views and reviews] *BMJ* 2009;**338**:112. [*BMJ*2009;338:a3178]